Figures computed from official regulatory filings — .
Analysttarget 31.29 USD (-16%) · consensus 3.22/5 · 1 buy · 8 hold · 0 sell
Ownershipinsiders 2.61% · institutions 105.48% · short 10.8% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for BIOLIFE SOLUTIONS INC only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
44 buys923 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Wichterman Troy | Other | $34.4K | SEC |
| Mathew Aby J. | Other | $20.7K | SEC |
| Werner Sean | Other | $15.4K | SEC |
| DE GREEF RODERICKtrack record | Other | $101.8K | SEC |
| Berard Todd | Other | $17.2K | SEC |
| Mathew Aby J. | Other | $22.2K | SEC |
| Berard Todd | Other | $12.6K | SEC |
| Wichterman Troy | Other | $36.3K | SEC |
| Werner Sean | Other | $8K | SEC |
| Berard Todd | Other | $8.1K | SEC |
| Wichterman Troy | Other | $23.5K | SEC |
| Mathew Aby J. | Other | $14.3K | SEC |
| Berard Todd | Other | $12.2K | SEC |
| DE GREEF RODERICKtrack record | Other | $72.3K | SEC |
| Wichterman Troy | Other | $24.4K | SEC |
| Mathew Aby J. | Other | $14.7K | SEC |
| Werner Sean | Other | $10.9K | SEC |
| Berard Todd | Other | $9.3K | SEC |
| Wichterman Troy | Other | $26.8K | SEC |
| Mathew Aby J. | Other | $16.4K | SEC |
| Casdin Partners Master Fund, L.P.track record | Sell | $15.4M | SEC |
| Casdin Partners Master Fund, L.P.track record | Sell | $5.9M | SEC |
| Casdin Partners Master Fund, L.P.track record | Sell | $6.8M | SEC |
| Mathew Aby J. | Other | $9.9K | SEC |
| Wichterman Troy | Other | $16.3K | SEC |